India COVID-19 Update: Antivirals, Eyes On HCQ-Azithromycin Data

Cipla Among Firms Prepping Favipiravir, Remdesivir, Baloxavir Generics

Development work for antivirals such as favipiravir and remdesivir seen as potential treatments for coronavirus is underway in India, with the former’s off-patent status making it more attractive. All eyes are also on data from a French study which highlights the potential of hydroxychloroquine and azithromycin as a COVID-19 treatment.

Coronavirus
Indian firms up activity around potential coronavirus treatments • Source: Shutterstock

As the world scrambles to repurpose approved treatments and develop new ones to tackle the deadly coronavirus, Indian firms are moving quietly alongside in sync, hoping to accelerate development activities or scale up plans for such potential therapies. Domestic firms are also keeping close watch on developments around an encouraging French study on the potential of hydroxychloroquine and azithromycin as a treatment for COVID-19.

Cipla Ltd., which has already indicated its readiness to move in quickly with generic supplies of AbbVie Inc..’s...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from R&D

Multiple Factors Driving Japan’s Pioneering Angiosarcoma Pipeline

 
• By 

Japan has emerged as a global leader in the development of new drugs for the rare cancer angiosarcoma, reflecting its rapidly ageing population and the limitations of current therapies.

Argenx Powers Ahead With Vyvgart’s Prefilled Syringe Launch

 

The Netherlands-headquartered company is enjoying huge success with Vyvgart in two autoimmune conditions, with a new prefilled syringe version reaching more patient groups.

Sanofi CFO Says Direct Sales To Patients ‘Certainly Worth Considering’

 
• By 

François Roger believes fixing inefficiencies is more important than playing with pricing.

Vyne Seeks Partner For Repibresib After Phase IIb Vitiligo Fail

 

The Phase IIb study failed its primary and a key secondary endpoint, but showed activity on another key secondary and an exploratory endpoint.

More from Scrip

Most Favored Nation Pricing: Trump Ups Pressure On Voluntary Action, Clarifies Demands

 

The new 60-day deadline for striking a deal with the drug industry underscores the challenges the Administration may be having in developing non-voluntary policies to achieve MFN pricing in the US.

Multiple Factors Driving Japan’s Pioneering Angiosarcoma Pipeline

 
• By 

Japan has emerged as a global leader in the development of new drugs for the rare cancer angiosarcoma, reflecting its rapidly ageing population and the limitations of current therapies.

Bristol’s Q2 Earnings Homerun Overshadowed By Clinical Trial Review Curveball

 
• By 

Second quarter revenue and EPS beat consensus and BMS raised its 2025 revenue guidance, but after multiple recent Phase III failures, executives said the company is reviewing studies with near-term readouts.